Review Article

Resident Stem Cells and Renal Carcinoma

Benedetta Bussolati, Alessia Brossa, and Giovanni Camussi

Laboratory of Renal and Vascular Physiopathology, Department of Internal Medicine, Molecular Biotechnology Centre and Research Centre for Molecular Medicine, University of Turin, C.so Dogliotti 14, 10126 Turin, Italy

Correspondence should be addressed to Giovanni Camussi, giovanni.camussi@unito.it

Received 13 January 2011; Accepted 16 March 2011

Academic Editor: Alejandro Martín-Malo

Copyright © 2011 Benedetta Bussolati et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

According to the cancer stem cell hypothesis tumors are maintained by a cancer stem cell population which is able to initiate and maintain tumors. Tumor-initiating stem cells display stem or progenitor cell properties such as self-renewal and capacity to re-establish tumors that recapitulate the tumor of origin. In this paper, we discuss data relative to the presence of cancer stem cells in human renal carcinoma and their possible origin from normal resident stem cells. The cancer stem cells identified in human renal carcinomas are not derived from the normal CD133+ progenitors of the kidney, but rather from a more undifferentiated population that retains a mesenchymal phenotype. This population is able to self-renewal, clonogenicity, and in vivo tumor initiation. Moreover, they retain pluripotent differentiation capability, as they can generate not only the epithelial component of the tumor, but also tumor endothelial cells. This suggests that renal cancer stem cells may contribute to the intratumor vasculogenesis.

1. Introduction

Emerging evidence showed that the capacity of a tumor to grow and propagate resides in a small population of tumor low proliferating cells, termed cancer stem cells (CSCs) or tumor-initiating cells [1]: the cancer stem cell hypothesis suggests that tumors are maintained by a CSC population which is chemo- and radioresistant and therefore can persist after treatment, leading to tumor recurrence [2, 3].

A tumor-initiating population able to sustain and maintain the tumor growth was identified in the majority of solid tumors [4–14]. These stem-like cells are identified by their ability to give rise to new serially transplantable tumors when xenografted in small number into immunodeficient mice, and to display stem or progenitor cell properties. In particular, they are characterized by self-renewal and capacity to re-establish tumor that recapitulates the tumor of origin, thanks to the ability to undergo asymmetric division leading to the generation of a progeny that can differentiate to produce tumor cells with heterogeneous phenotype [3].

Renal carcinoma is a common form of urologic tumor, representing 3% of total human malignancies, with a high metastatic index at the diagnosis and a high rate of relapse because of the resistance to radiations and chemotherapies [15]. Due to the ability of CSCs to recapitulate the tumor, strategies of targeting CSCs should be taken into account. Recent encouraging data in other tumors have provided proof of principle that selective targeting of CSCs is possible [16–18].

In this paper, we will present the existing data of the literature on the role of stem cells in human renal carcinoma. Normal stem cells may participate to renal carcinomas, sustaining tumor growth and vascularization. In addition, tumor stem cells with tumor-initiating ability have been described (Table 1), suggesting the relevance of CSCs in generation, growth, and recurrence of renal carcinomas. Finally, evidence will be presented on the ability of renal CSCs to differentiate into endothelial cells and to participate to tumor vasculogenesis.

2. Cancer Stem Cell Hypothesis for Tumor Origin

The concept of a less differentiated, pluripotent cell forming cancer relies on common properties and phenotype of tumor stem cells and embryonic or adult normal stem cells. This could be due to acquirement of stem cell properties by fully
differentiated proliferating cells following accumulation of critical mutations or alternatively to the origin of CSCs from mutated normal stem cells. Several evidences support both possibilities [19, 20]. It has been shown that the epithelial-to-mesenchymal transition of tumors enhances the number of CSCs [21], supporting the notion that the dedifferentiation process may favor the stem-related phenotype of tumors. Indeed, recent studies showing that activation of critical embryonic genes or oncogenes may induce pluripotency in differentiated cells [22] further support this possibility.

Other evidences support the notion that tumorigenesis may originate from mutation of normal adult tissue resident stem cells or from deriving progenitor cells that have acquired mutations that enable them to escape from niche control [23]. Alternatively, deregulation of extrinsic factors within the niche might lead to uncontrolled proliferation of stem cells and tumorigenesis. This concept is supported first by the fact that stem cells have, or can, reacquire the self-renewal properties needed for maintaining and expanding stem cell numbers [24]. Second, the stem cell pool is anchored to the niche and is maintained through the entire life and therefore may have the time to acquire mutations [25]. This is particularly pertinent to cancers of continually renewing cell populations, such as those of the intestine, stomach, and skin [26, 27]. Under this light, it can be proposed that cancers may represent a maturation arrest of stem cells. Depending on the differentiation state of the mutated cell, from stem to progenitor to differentiated cells, CSCs may display different stem properties and malignancy.

3. Normal Renal Stem Cells

According to the hierarchical lineage view of tumors [20], renal tumors may arise from the embryonic stem cell compartment, providing rise to the Wilms tumor, as well as from the stem cell pool of the adult kidney or from the deriving progenitors, giving rise to the different histologic types of carcinomas (undifferentiated, clear-cell, papillary carcinomas) (Figure 1). Embryonic stem cells have been described in the embryonic kidney until relatively late in gestation in the nephrogenic zone, from which they have been isolated and characterized [28]. Comparative analysis of embryonic stem cells and of the pediatric renal malignancy Wilms tumor showed that Wilms tumor resulted from a differentiation arrest of embryonic progenitors committed to the nephrogenic lineage [29]. These cells were present in the tumor both as undifferentiated blastema and as renal differentiated elements.

In the human adult kidney, CD133+ renal progenitor cells have been characterized by our group in the renal cortex from the tubule/interstitium [30]. In addition, multipotent CD133+/CD24+ stem cells have been isolated from the Bowman’s capsule [31]. A genomic characterization of multipotent CD133+/CD24+ renal progenitor cells from glomeruli and tubules of adult human kidney revealed no significant differences in the gene expression patterns suggesting that tubular and glomerular renal progenitor cells represent a genetically homogeneous population [32]. Indeed, the presence of cytokeratin expression by the CD133+/CD24+ cells suggests an epithelial commitment that characterizes these cells as epithelial progenitors.

4. CD133+/CD34− Cells and Renal Carcinomas

Following the stem cell view of tumor generation, CD133 has been investigated as a marker for identification of CSCs in renal carcinomas. A small population of CD133+/CD34− cells (less than 1% of the total cells) was found in human renal carcinomas [33]. These cells, that represent a progenitor cell population in the normal kidney [30], showed the same mesenchymal phenotype and differentiative ability of their normal counterpart. They expressed CD73, CD44, CD29, the developmental renal marker PAX-2, and the mesenchymal marker vimentin and were able to differentiate both in endothelial and epithelial cells in vitro and in vivo [33]. When injected subcutaneously within Matrigel in immunodeficient mice, CD133+/CD34− stem cells were not able to form tumors suggesting that they did not represent the tumor-initiating cell population [33], at variance of CD133+ cells derived from brain, prostate and pulmonary tumors [5, 10, 13, 34]. The observation that CD133+/CD34− cells cultured in presence of the supernatant differentiated in endothelial cells led to the idea that the tumor microenvironment could be involved in the endothelial commitment of these renal progenitors. Indeed, when cotransplanted with renal tumor cells, at a 1:100 ratio, CD133+/CD34− cells significantly enhanced tumor engraftment, growth, and vascularization, suggesting that these progenitors may produce a growth factor environment favoring tumor growth and vascularization [33]. Recently, D’Alterio et al. evaluated the expression of CD133 on samples of human renal clear cell carcinoma, showing that CD133 expression did not correlate to clinical pathological features or affected patients prognosis [35].

5. CD105+ Renal Cancer Stem Cells

We recently identified a population of CD105+ tumor-initiating cells in renal human carcinomas [36]. The mesenchymal origin of these cells is in accordance with the

---

**Table 1: Different populations of stem cells identified in human renal carcinomas and role in tumor growth. N. D.: not done.**

| Identification method | Role in carcinogenesis | References |
|-----------------------|------------------------|------------|
| Expression of CD105   | Tumor initiation        | Bussoleti et al. [36] |
| Expression of CD133   | Nontumor initiation     | Bruno et al. [33] |
| Side population       | N.D.                   | Addla et al. [37] |
| Sphere formation      | Tumor initiation        | Zhong et al. [39] |
|                       |                       | Huges et al. [38] |
mesenchymal origin of the kidney and with the mesenchymal phenotype of stem cells found in normal rodent kidney as well as in the human embryo [40–42]. By magnetic cell sorting of specimens of human renal carcinomas, our laboratory isolated a subpopulation of cell expressing the mesenchymal marker CD105, representing less than 10% of the tumor mass. The CD105+ population induced tumors in SCID mice with 100% incidence, whereas the CD105− population induced tumors with only 10% incidence. CD105+ cells expressed markers characteristic of mesenchymal stem cells, such as CD44, CD90, CD146, CD73, CD29, and vimentin. Characterization of the phenotype of CD105+ clones revealed several stem cells properties, such as clonogenic ability, sphereformation in presence of nonadhesive cell culture medium, expression of stem cells markers (Nanog, Oct4, Musashi, Nestin, and the embryonic marker Pax2), lack of differentiative epithelial markers, in vitro differentiation on both endothelial and epithelial cell types [36]. In addition, in vivo they generated serially transplantable carcinomas containing a small population of undifferentiated CD105+ tumorigenic cells and differentiated CD105− tumor epithelial cells. Only the CD105+ population was able to propagate the tumor [36]. These data suggest that the CD105+ cells represent a tumor-initiating cell population that may originate from resident renal stem cells with mesenchymal characteristics. The lack of CD133 and CD24 expression, which are present in adult and embryonic renal progenitors [30, 31, 43] by tumor-initiating CD105+ clones, suggests that they are not derived from the CD133+ population. Moreover, CD133+ progenitors previously isolated from renal tumors did not express CD105 and were not tumorigenic [33].

6. Sphere-Derived CSCs

Generation of spheres is considered a useful culture system to select for CSCs. Cells growing as tumor spheres in serum-free medium supplemented with EGF and bFGF were isolated from the renal cell carcinoma cell line SK-RC-42. This sphere-forming population showed the ability of self-renewing in vitro and in vivo, higher mRNA expression levels of several “stemness” genes, stronger tumorigenicity and resistance to chemotherapeutic agents and irradiation compared with the monolayer adherent cells [39].

7. Side Population in Renal Carcinomas

According to the fact that the isolation of CSCs using specific markers can be very difficult, Addla et al. identified a side population (SP) from both normal and malignant renal epithelial cells [37], using the Hoechst 33342 dye efflux assay developed by Goodell et al. in the hematopoietic system [44]. The SP of normal kidney expresses the same markers identified by Bussolati et al. [30]. In addition, the authors found a differential expression of CD133 marker between

---

**Figure 1:** Scheme representative of the possible stem cell origin of renal CSCs. Mutations/epigenetic alterations of the renal embryonic stem cells may originate the pediatric malignancy Wilm’s tumor. The different histologic types of renal carcinomas of the adult may derive from mutations occurring in the stem cell compartment of the adult kidney. The lack of CD133+ marker in renal CSCs may support the idea of an origin from a yet unidentified mesenchymal population, which is ahead of CD133+ renal progenitors in the differentiation lineage. Alternatively, a process of de-differentiation of renal progenitors or mature cells could be involved.
the side population of normal and malignant kidney, being
CD133 only expressed by the normal SP. According to
these findings, the loss of CD133 might be a very early
event in stem cells differentiation and possibly in malignant
transformation [37]. The characterization of SP cells with
high brilliance synchrotron-FITR spectroscopy revealed the
presence of different subpopulations of cells, with different
cellular biochemistry [38], but actually there is no evidence
of a differential role of these subpopulations in carcinogene-
sis, neither any specific marker has been identified.

8. Renal CSCs and Endothelial Differentiation

The stemness and the origin of CSCs from tissue stem/
progenitor cells may support the capacity of CSCs to dif-
ferentiate in cell types present in the tumor other than the
epithelial tumor cells. In renal carcinomas CD105+ CSCs
were shown to be bipotent, as they were able to differentiate
into tumor epithelial and endothelial cells both in vitro
and in vivo [36]. The evidence of an in vivo differentiation
of stem cells into endothelial cells was provided by the
observation that at least a fraction of the vessels present in
the transplanted tumors originated from tumor stem cells
were of human origin. Clonal studies showing endothelial
differentiation of single-cell-derived spheres or clonal cell
lines derived from renal CSCs confirmed the multipotency
of renal CSCs. This endothelial differentiation has been also
shown for CSCs derived from glioblastomas [45–48], hep-
atocellular carcinomas [49], ovarian [50] and breast cancer
[51], suggesting that this is rather a general phenomenon
applicable to stem cells in different tumors, possibly due
to the maintenance of stem properties in cancer stem cells.
Of interest, a mechanism involved in the endothelial differ-
entiation of tumor stem cells was reported to be hypoxia
[51]. This concept is of particular relevance in tumor anti-
giogenic therapy, as therapy-induced hypoxia may promote
alternative strategies to support tumor vascularization and
induce a switch from normal to cancer stem-dependent
vascularization. Anti-angiogenic therapies currently implied
in the treatment of renal carcinoma [52] should therefore
be aimed to target not only normal, but also tumor-derived
endothelial cells.

9. Conclusions

Altogether the data of the literature indicate that renal car-
cinomas possess a population of CSCs with mesenchymal
properties (Table 1). These CSCs have a high tumorigenic
ability and are resistant to chemo- and radiotherapy [36, 39].
In addition, the differentiation of CSCs into endothelial
cells and the possible role of infiltrating normal stem cells,
such as CD133+ resident cells and MSCs, suggest a complex
relationship between tumor and its microenvironment, that
should be taken into account for the design of future
therapies.

Concerning the stem cell origin of renal CSCs, the data
are still discordant. The lack of tumorigenicity of CD133+
cells [33] is in contrast with the idea that, also in the kidney,
carcinomas originate from renal progenitors expressing
CD133. A possible explanation is the origin of renal carci-
nomas from a more undifferentiated stem cell compartment
(Figure 1). Alternatively, it could be postulated that a true
stem cell compartment is lacking in the renal tubuli. In
particular, the plastic phenotype of tubular cells, evidenced
by the finding that they are in the G1 phase of the cell
cycle [53], can suggest that tubular cells may modulate their
phenotype toward stemness in response to environmental
stimuli. According to this idea, being the kidney a low
regenerating organ, a different mechanism could occur
in respect to highly proliferating organs such as the gut
implying the de-differentiation of mature cells.

References

[1] T. Reya, S. J. Morrison, M. F. Clarke, and I. L. Weissman, “Stem
cells, cancer, and cancer stem cells,” Nature, vol. 414, no. 6859,
pp. 105–111, 2001.
[2] P. Dalerba, R. W. Cho, and M. F. Clarke, “Cancer stem cells:
models and concepts,” Annual Review of Medicine, vol. 58, pp.
267–284, 2007.
[3] M. F. Clarke, J. E. Dick, P. B. Dirks et al., “Cancer stem cells—
perspectives on current status and future directions: AACR
workshop on cancer stem cells,” Cancer Research, vol. 66, no.
19, pp. 9339–9344, 2006.
[4] M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison,
and M. F. Clarke, “Prospective identification of tumorigenic
breast cancer cells,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 100, no. 7, pp.
3983–3988, 2003.
[5] S. K. Singh, I. D. Clarke, M. Terasaki et al., “Identification of
a cancer stem cell in human brain tumors,” Cancer Research,
vol. 63, no. 18, pp. 5821–5828, 2003.
[6] S. K. Singh, C. Hawkins, I. D. Clarke et al., “Identification of
human brain tumour initiating cells,” Nature, vol. 432, no.
7015, pp. 396–401, 2004.
[7] C. A. O’Brien, A. Pollett, S. Gallinger, and J. E. Dick, “A
human colon cancer cell capable of initiating tumour growth
in immunodeficient mice,” Nature, vol. 445, no. 7123, pp. 106–
110, 2007.
[8] L. Ricci-Vitiani, D. G. Lombardi, E. Pilozi et al., “Identification
and expansion of human colon-cancer-initiating cells,”
Nature, vol. 445, no. 7123, pp. 111–115, 2007.
[9] C. Li, D. G. Heidt, P. Dalerba et al., “Identification of
pancreatic cancer stem cells,” Cancer Research, vol. 67, no. 3,
pp. 1030–1037, 2007.
[10] A. T. Collins, P. A. Berry, C. Hyde, M. J. Stower, and N. J.
Maitland, “Prospective identification of tumorigenic prostate
cancer stem cells,” Cancer Research, vol. 65, no. 23, pp. 10946–
10951, 2005.
[11] S. A. Bapat, A. M. Mali, C. B. Koppikar, and N. K. Kurrey,
“Stem and progenitor-like cells contribute to the aggressive
behavior of human epithelial ovarian cancer,” Cancer Research,
vol. 65, no. 8, pp. 3025–3029, 2005.
[12] D. Fang, T. K. Nguyen, K. Leishear et al., “A tumorigenic
subpopulation with stem cell properties in melanomas,”
Cancer Research, vol. 65, no. 20, pp. 9328–9337, 2005.
[13] A. Eramo, F. Lotti, G. Sette et al., “Identification and expansion
of the tumorigenic lung cancer stem cell population,” Cell
Death and Differentiation, vol. 15, no. 3, pp. 504–514, 2008.
increased angiogenesis capability and drug resistance compared with normal endothelial cells,” Clinical Cancer Research, vol. 15, no. 15, pp. 4838–4846, 2009.

[50] A. B. Alvero, H. H. Fu, J. Holmberg et al., “Stem-like ovarian cancer cells can serve as tumor vascular progenitors,” Stem Cells, vol. 27, no. 10, pp. 2405–2413, 2009.

[51] B. Bussolati, C. Grange, A. Sapino, and G. Camussi, “Endothelial cell differentiation of human breast tumour stem/progenitor cells,” Journal of Cellular and Molecular Medicine, vol. 13, no. 2, pp. 309–319, 2009.

[52] F. L. Heldwein, B. Escudier, G. Smyth, C. A. V. Souto, and G. Vallancien, “Metastatic renal cell carcinoma management,” International Brazilian Journal of Urology, vol. 35, no. 3, pp. 256–270, 2009.

[53] A. Vogtseder, N. Picard, A. Gaspert, M. Walch, B. Kaissling, and M. Le Hir, “Proliferation capacity of the renal proximal tubule involves the bulk of differentiated epithelial cells,” American Journal of Physiology, vol. 294, no. 1, pp. C22–C28, 2008.